Andere Sprachen Corbus Pharmaceuticals Holdings, Inc.

Aktien

A3D54P

US21833P3010

CRBP

Verzögert Nasdaq Andere Börsenplätze 18:32:01 07.06.2024			% 5 Tage	% 1. Jan.
45,98 ^USD	-1,32 %		+7,44 %	+661,34 %

03.06.	CORBUS PHARMACEUTICALS HOLDINGS, INC. : Bewertung von Oppenheimer kaufen	ZM
01.06.	Corbus Pharmaceuticals präsentiert auf der ASCO-Konferenz ein positives klinisches Update zu SYS6002 (CRB-701)	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Corbus Pharmaceuticals Reaches 2-Year High After Drug Results	03.06.
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024	01.06.
Corbus Pharmaceuticals Presents Positive Clinical Update on SYS6002 (CRB-701) at ASCO Conference	01.06.
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference	30.05.
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting	23.05.
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference	09.05.
Corbus Pharmaceuticals: Q1 Earnings Snapshot	07.05.
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	07.05.
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum	01.05.
Certain Restricted Stock Units of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01.05.
Certain Warrants of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01.05.
Certain Options of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01.05.
Certain Common Stock of Corbus Pharmaceuticals Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01.05.
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting	24.04.
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	02.04.
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC	02.04.
Corbus Pharmaceuticals Files Mixed Shelf	13.03.
Health Care Climbs on Risk Appetite -- Health Care Roundup	12.03.
Corbus Pharmaceuticals: Q4 Earnings Snapshot	12.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Corbus Pharmaceuticals Holdings, Inc.

Aktien

A3D54P

US21833P3010

CRBP

Andere Sprachen

Filter